Revolution Medicines heads into its Q1 2026 earnings release with a rare alignment: a landmark clinical publication, a collapsing short position, and a Wall Street analyst community that has spent two weeks racing to raise targets.
The most striking development this week is not on the trading desk — it's in a journal. Phase 1/2 data for daraxonrasib in pancreatic cancer was published in the New England Journal of Medicine today, an event that carries unusual weight for a pre-revenue oncology name. The data supports continuation of the Phase 3 trial, and the company simultaneously reported Q1 results with operating expense guidance of $1.7–1.8 billion for the full year 2026. The EPS print of $(2.29) missed the $(1.82) consensus estimate, reflecting the burn profile of a company still deep in late-stage development.
The positioning story is one of short sellers stepping back. Short interest has fallen to 7% of the free float — down from roughly 10.5% at mid-April peaks, a drop of more than 2.5 percentage points in under three weeks. The retreat began sharply around April 23, when shorts covered more than 2.5 million shares in a single session. The lending market reflects this easing: availability remains comfortable at around 1.8%, cost to borrow is just 0.49% annualised, and the ORTEX short score has pulled back to 45.4 from above 49 two weeks ago. None of these readings suggest squeeze risk — this is an orderly unwinding. The put/call ratio, at 1.28, has drifted down from its 20-day average of 1.41, moving one standard deviation below the mean. Options traders are less defensively positioned than they were a month ago, when the PCR ran as high as 1.72.
The Street has been uniformly constructive. Over the past three weeks, targets have moved sharply higher across the board — Stifel raised to $215 from $170, Evercore ISI Group pushed to $200 from $140, and Needham went to $186 from $145. Leerink Partners lifted to $171 from $147 just last week. The mean consensus target now sits at $174, against a close of $147.21 — implying roughly 18% upside, though the stock has already rallied 48% over the past month, compressing that gap considerably. The bull case centres on first-mover positioning in RAS-addicted cancers and a projected US pancreatic cancer market of around $18 billion. Bears point to the Phase 3 trial's dual-primary-endpoint design, the EPS miss, and the competitive pressure on zoldonrasib in KRASG12D+ lung cancer. Factor scores are mixed: EPS momentum is weak over a 30-day window (13th percentile) but sits near the median over 90 days, and the EPS surprise score is solid at the 73rd percentile.
Insider activity leans net-selling. CEO Mark Goldsmith sold 120,000 shares on April 15 at around $150 — a $18 million transaction that stands out in size even within a broader pattern of routine C-suite sales. A cluster of smaller executive sells occurred in late March at prices around $94–97, well below current levels, meaning they have in aggregate sold into the rally. Net shares transacted over 90 days are marginally positive at roughly 228,000, a figure dominated by option-related mechanics rather than open-market buying conviction.
With Q1 results now out, EPS guidance set, and the NEJM publication landing tonight, the next focal point is how analysts absorb the miss on earnings per share against the clinical data validation. The gap between the consensus target and the current price, already compressed by the 48% one-month run, is the tension worth tracking.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
